This white paper distils insights from a closed-door roundtable with experienced biotech CFOs, exploring how financial leadership is evolving amid volatile markets, shifting policy, and unpredictable clinical outcomes. The discussion highlights how today’s CFOs operate far beyond traditional finance — acting as strategic co-pilots who balance discipline with agility while helping their organisations navigate uncertainty.

Core themes include decision-making with imperfect information, the trade-offs between financing and partnering, the dynamics of board and investor alignment, and the central role of the CFO–CEO partnership in maintaining organisational coherence. The paper also examines the qualities shaping the next generation of biotech CFOs — from scenario thinking and external storytelling to fostering internal clarity and confidence.

The result is a candid look at how modern CFOs translate complexity into direction, influence, and execution at the most pivotal moments for their companies.

In September 2025, we brought together senior leaders across business development, commercial strategy and HEOR for an in-depth roundtable on one of the most pressing questions facing early-stage biotechs: what does it truly mean to build for value in phase 1 and 2?

With investors, partners and analysts scrutinising access, differentiation and long-term viability much earlier than before, the group explored how early teams can make better decisions despite limited resources and rising expectations.

This white paper distils the insights from that discussion, highlighting where value is created or lost in early development and what leaders can do to improve outcomes. It offers a grounded view of how experienced leaders are approaching these challenges and what can help organisations make more informed early-stage decisions.

This report explores the art of influencing without authority in biopharma through interviews with Alliance Managers and Chiefs of Staff.

These roles drive impact without direct control, relying on trust and collaboration. It highlights their strategies, challenges, and successes in aligning stakeholders in complex organizations. Through real-world examples, the report offers actionable insights for mastering strategic influence.

Navigating the early stages of biotech development is fraught with challenges and opportunities. For preclinical or clinical-stage biotech companies, having the right Chief Business Officer can be the difference between success and stagnation. This article explores the critical timing and reasons for hiring a skilled CBO, whether on a permanent or fractional basis, and how they can propel your biotech company forward.

"Building Bridges: Insights into Business Development and Partnerships in Biopharma."

Anjali Kumar - VP & Head of Business Development - Cellarity

In this article, we feature Anjali Kumar, a distinguished leader with over 25 years of experience in the biopharmaceutical industry. Currently, she serves as VP and Head of Business Development at Cellarity, a Flagship Pioneering company.

Anjali's impressive career includes roles at major companies such as Johnson & Johnson, Shire, Wyeth, and Pharmacia & Upjohn, as well as emerging firms like Flexion Therapeutics and Critical Therapeutics.

She has significantly contributed to drug discovery and development, leading over 50 deep integrated opportunity assessments and numerous transactions including M&A and license agreements.

At Cellarity, she drives business development for a unique AI/ML-enabled platform.

Additionally, Anjali is a member of the External Advisory Board at Georgia Tech and holds a PhD in Bioengineering from the same institution.

Join us as Anjali shares her journey, the challenges and opportunities in the industry, and her vision for the future. We explore her insights on building successful partnerships and driving innovation in biopharma.

"Building Bridges: Insights into Business Development and Partnerships in Biopharma."

Ravneesh Sachdev - Partner and Head of Business Development at Apple Tree Partners

We delve into the career and insights of Ravneesh Sachdev, a leading figure in biopharma business development. Currently a Partner and Head of Business Development at Apple Tree Partners, a venture capital firm focused on life sciences investment, Ravneesh shares his extensive experience in shaping strategic partnerships and driving innovation in the industry. From his pivotal roles at Acceleron Pharma and Sage Therapeutics to his contributions at Pfizer and other major companies, Ravneesh offers a wealth of knowledge on navigating challenges and seizing opportunities in biopharma.

Join us to explore his journey, key accomplishments, and vision for the future of biopharma partnerships.